Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Argos Aims To Automate Cell-Based Cancer Therapy

This article was originally published in Start Up

Executive Summary

Eventually, someone is going to have clinical and commercial success with a personalized cancer therapy. Learning from the mistakes of Dendreon and others, Argos Therapeutics expects to be first, and automation is its key.

Advertisement

Related Content

Argos Nears Phase III Results For Precision Cancer Immunotherapy
Unum Therapeutics Inc.
Cancer Immunotherapy: Mixing, Matching, And Making Nice
At Regen Med Meeting, Cardio3, Others Grapple With Complex Market
No Happy Endings For Dendreon As It Closes Another Chapter
Cancer Immunotherapy Reaches A Tipping Point

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC092554

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel